Turner Investments’s Avadel Pharmaceuticals AVDL Stock Holding History

Turner Investments’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-59,598	Closed	-$619K	–	219
2016 Q4	$619K	Sell	59,598 -10,460	-15%	-$115K	0.25%	134
2016 Q3	$869K	Sell	70,058 -47,280	-40%	-$618K	0.29%	114
2016 Q2	$1.26M	Sell	117,338 -28,810	-20%	-$307K	0.39%	78
2016 Q1	$1.61M	Sell	146,148 -93,160	-39%	-$925K	0.44%	81
2015 Q4	$2.92M	Buy	239,308 +104,340	+77%	+$1.63M	0.6%	60
2015 Q3	$2.2M	Sell	134,968 -60,277	-31%	-$1.33M	0.45%	74
2015 Q2	$4.14M	Buy	195,245 +36,501	+23%	+$655K	0.76%	39
2015 Q1	$2.85M	Sell	158,744 -61,044	-28%	-$956K	0.51%	66
2014 Q4	$3.77M	Sell	219,788 -253,200	-54%	-$3.62M	0.45%	51
2014 Q3	$6.77M	Buy	472,988 +188,614	+66%	+$2.71M	0.41%	64
2014 Q2	$4.27M	Buy	+284,374	New	+$3.43M	0.19%	157

Other funds holding AVDL

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.87B AUM 46.94% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Turner Investments's AVDL Position: Q1 2017 in Review

Turner Investments sold out of Avadel Pharmaceuticals (AVDL) in Q1 2017, closing a stake of 59,598 shares — an estimated $619K sold.

Turner Investments first reported a position in AVDL in Q2 2014 and held it in 11 quarters. The position peaked at $6.77M in Q3 2014. 74 funds tracked by Wall St. Rank hold AVDL as of Q1 2017.

Turner Investments reported no remaining Avadel Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Turner Investments sold 59,598 Avadel Pharmaceuticals shares in Q1 2017, an estimated $619K.
Turner Investments first reported a position in Avadel Pharmaceuticals in Q2 2014 and held it in 11 quarters.
Turner Investments's Avadel Pharmaceuticals position peaked at $6.77M in Q3 2014.
74 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2017.

Based on Turner Investments's 13F filing for Q1 2017, filed 11 May 2017.